# US 2020/0399706 A1 · Immune Gene Signatures in Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399706 A1
- Document ID: US20200399706A1
- Status: Published application
- Kind: A1
- Application number: 16/868,293
- Filed: 2020-05-06
- Published: 2020-12-24
- Earliest claimed: 2010-01-29
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Inventors: James J. Mulé; Domenico Coppola; Timothy J. Yeatman; Audrey Loboda; Michael V. Nebozhyn
- Web page: https://patentgrep.com/patent/US20200399706A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- G01N 33/575: for cancer
- G01N 33/57515: of the breast
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

## Claims

### Claim 1

A method of treating a subject who has a solid tumor, the method comprising: obtaining cells from the tumor; determining gene expression levels of chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), CCL19, CCL21, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, and CXCL13 in the tumor cells; comparing the tumor gene expression levels to reference gene expression levels; identifying a subject who has tumor gene expression levels above the reference gene expression levels; and administering an immunotherapy treatment for cancer to a subject who has tumor gene expression levels above the reference gene expression levels.

### Claim 2 (depends on 1)

The method of claim 1, wherein determining gene expression levels comprises determining protein levels or mRNA levels.

### Claim 3 (depends on 2)

The method of claim 2, wherein determining mRNA levels comprises using reverse transcription polymerase chain reaction or a gene chip.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tumor is non small cell lung cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the treatment comprises administering cyclophosphamide; anti-interleukin-2R immunotoxin; and/or an anti-cancer antibody selected from the group consisting of anti-CD137, anti-programmed death-1 receptor (PD1), and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4).

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibody is anti-CD137.

### Claim 8 (depends on 6)

The method of claim 6, wherein the antibody is anti-PD1.

### Claim 9 (depends on 6)

The method of claim 6, wherein the antibody is anti-CTLA-4.